ZNF217 and esophagitis: A total of 11 patients carried ZNF217 amplifications, ten of which developed grade 2 or higher pneumonitis and esophagitis (90.9% vs. 36.9%, OR=16.7 [95% CI, 2.24-748.4], P=0.0007, Figure 7D).